Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $18.21M rose 144.9% year over year, ahead of the +60.0% change in trailing-twelve-month research & development. Sequentially, it rose 7.5% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.

Context

  • Research & development amounted to 339.4% of revenue in FY2025, down 61.3 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +144.9% holds above the trailing-twelve-month pace of +60.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.21M+7.5% QoQ
Last fiscal yearDec 2025
$44.49M+10.0% YoY
LTMMar 2026
$55.26M+60.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+144.9%——
1 year+10.0%——
3-year CAGR-18.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
44.49M USD
Year-over-year change
+10.0%
4-year CAGR
-10.3%

Research & Development vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +60.0% is the 3rd highest of 10, against a peer median of -7.1%.
  • Research & development amounts to 314.8% of revenue for TNXP, versus a peer median of 1590.8%.
TNXP Competitors
Research & Development for TNXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$100.48M USD-23.9%-30.4%1590.8%
NKTXNkarta, Inc.LTM Mar 2026$88.91M USD-7.1%-0.2%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$69.93M USD+20.4%+34.8%—
FBRXForte Biosciences, Inc.LTM Mar 2026$65.43M USD+123.8%+118.4%—
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$55.26M USD+60.0%-18.4%314.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
IPHAInnate Pharma S.A.FY2025€43.62M EUR-16.1%-5.5%1565.1%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$37.82M USD-33.6%-23.5%3297.1%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M USD-29.5%+13.5%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding TNXP) —-7.1%-0.2%1590.8%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.